Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation: Results from the dresden NOAC registry

Thrombosis and Haemostasis

Volumn 113, Issue 6, 2015, Pages 1247-1257

  Beyer Westendorf, Jan ^a   Ebertz, Franziska ^a   Förster, Kati ^a   Gelbricht, Vera ^a   Michalski, Franziska ^a   Köhler, Christina ^a   Werth, Sebastian ^a   Endig, Heike ^a   Pannach, Sven ^a   Tittl, Luise ^a   Sahin, Kurtulus ^b   Daschkow, Katharina ^a   Weiss, Norbert ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Institute for Clinical Research and Statistics   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; Dabigatran

Indexed keywords

ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; ANTITHROMBIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAY CARE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SUDDEN CARDIAC DEATH; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; GERMANY; INTENTION TO TREAT ANALYSIS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; REGISTER; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME FACTOR; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; DRUG ADMINISTRATION SCHEDULE; EMBOLISM; FEMALE; GERMANY; HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931287775     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0954     Document Type: Article

References (23)

1. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e44S-e88S.
2. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-1166.
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
4. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-1896.
5. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from Vitamin-K antagonists to dabigatran or rivaroxaban in daily care -results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; Epub ahead of print.
6. Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
7. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
8. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation 2014; Epub ahead of print.
9. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open 2013; 3.
10. Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Cmaj 2013; 185: E121-127.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
12. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
13. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
14. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc 2005; 293: 690-698.
15. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circulation Cardiovasc Qual Outcom 2013; 6: 567-574.
16. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6: 1500-1506.
17. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
18. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circulation Cardiovasc Qual Outcom 2010; 3: 624-631.
19. Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012; 172: 1687-1689.
20. Lane DA, Lip GY. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: 381-383.
21. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. Curr Pharmaceut Des 2014; 21: 533-543.
22. Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-473.
23. Clarkesmith DE, Pattison HM, Lip GY, et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PloS one 2013; 8: e74037.